Response to treatment with tocilizumab of reactive arthritis induced by intravesical bacillus Galmette-Guérin unresponsive to DMARDs.
Kevin
K
Kwan
Sneha
S
Bharadwaj
Charles
C
Inderjeeth
D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D016918:Arthritis, Reactive / Q000188:drug therapy* / Q000276:immunology; D001500:BCG Vaccine / Q000009:adverse effects*; D057915:Drug Substitution; D006801:Humans; D008297:Male; D017211:Treatment Failure; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000628:therapy
D000276:Adjuvants, Immunologic; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D001500:BCG Vaccine; C502936:tocilizumab